A Covid-19 vaccine developed in China has shown success in mid-stage trials. The report published by the scientific journal The Lancet was carried out by Prof. Yanjun Zhang and his team on the CoronaVac vaccine.
Although the results are positive the process still requires further testing. The CoronaVac by Sinovac Biotech still needs to go through the third phase of testing.
Prof. Zhu Fengcai, one of the paper’s authors, said the results are based on 144 participants in the phase 1 trial and 600 in the phase 2 trial – meant the vaccine was “suitable for emergency use”.
Still no data is available for the ongoing large-scale phase 3 trials.
The announcement comes after European and US vaccines reported successful data from large late-stage trials.
Three vaccines, developed in the US, Germany and Russia, have all released data suggesting efficiency of more than 90%, after trials with tens of thousands of people.
This was confirmed by the European Commission approving a 5th contract with CureVac for up to 405 million doses of the Covid-19 vaccine.
The contract provides for the initial purchase of 225 million doses on behalf of all EU Member States, plus an option to request up to a further 180 million doses, to be supplied once a vaccine has proven to be safe and effective against Covid-19.
In the meantime, the World Health Organisation is working hard through its COVAX programme to assure equitable access to COVID-19 diagnostics, treatments and vaccines to all countries. WHO has received support from 171 countries but not the USA. However, the US electoral results may have a shade of light for cooperation.
The alliance expects to hold talks with the incoming team of U.S. President-elect Joe Biden about collaborating on global distribution and collaboration. Although, President-elect Biden hasn’t made a formal announcement on the matter yet, his team has already been working on a plan to “offset the cost of bringing any eventual vaccines to developing countries.”